Skip to main content

FDA Orders Halt On The Sale of Vaginal Mesh Products

FDA Orders Halt On The Sale of Vaginal Mesh Products

FDA Orders Halt On The Sale of Vaginal Mesh Products

Introduction

On Tuesday, April 16, the U.S. Food and Drug Administration (FDA) ordered Boston Scientific and Coloplast to stop the sale of their pelvic mesh products in the U.S., typically used to treat pelvic organ prolapse (POP) and incontinence.

The agency had reclassified the devices as high-risk in 2016 when the manufacturers were required to submit premarket approval applications to keep their pelvic mesh product in the U.S. market. The order is applicable to Boston's Uphold Lite Vaginal Support System and Xenform Soft Tissue Repair System and Coloplast AS' Restorelle DirectFix Anterior Mesh. Both the manufacturers are given 10 days to submit a plan about the product withdrawal from the market. According to the agency, all other mesh products meant for repair pelvic organ prolapse were pulled out from the market in 2018 when their manufacturers failed to submit premarket approval applications. Talking about the market withdrawals, Dr. Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health, said, in order to keep the devices on the market, evidence need to be added in the premarket applications that indicate them as a safer alternative to surgery. Boston Scientific & Coloplast are the only two remaining makers of the mesh devices, and they failed to prove the long-term safety and effectiveness of their devices. The FDA suggested that women who are planning to have transvaginal mesh repair of POP must discuss other treatment methods with their doctors.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!